Rein Therapeutics (NASDAQ:RNTX) Director Rickenbach Josef Von Acquires 23,190 Shares

Rein Therapeutics Inc. (NASDAQ:RNTX) Director Rickenbach Josef Von acquired 23,190 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was purchased at an average cost of $1.06 per share, with a total value of $24,581.40. Following the purchase, the director directly owned 58,014 shares in the company, valued at approximately $61,494.84. This trade represents a 66.59% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Rein Therapeutics Stock Up 4.7%

RNTX stock opened at $1.11 on Friday. Rein Therapeutics Inc. has a 12-month low of $0.95 and a 12-month high of $2.18. The company has a market cap of $94.95 million, a price-to-earnings ratio of -0.58 and a beta of 1.42. The company has a 50 day moving average of $1.33 and a two-hundred day moving average of $1.31.

Rein Therapeutics (NASDAQ:RNTX) last released its earnings results on Friday, May 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.30. On average, research analysts anticipate that Rein Therapeutics Inc. will post -1.63 EPS for the current year.

Institutional Investors Weigh In On Rein Therapeutics

Several institutional investors have recently modified their holdings of RNTX. Susquehanna International Group LLP acquired a new stake in shares of Rein Therapeutics during the 3rd quarter worth approximately $35,000. HRT Financial LP acquired a new stake in shares of Rein Therapeutics during the 4th quarter worth approximately $38,000. Chicago Partners Investment Group LLC grew its position in shares of Rein Therapeutics by 32.2% during the 1st quarter. Chicago Partners Investment Group LLC now owns 41,048 shares of the company’s stock worth $53,000 after buying an additional 10,000 shares during the period. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Rein Therapeutics during the 2nd quarter worth approximately $68,000. Finally, Jane Street Group LLC acquired a new stake in shares of Rein Therapeutics during the 4th quarter worth approximately $72,000. Institutional investors and hedge funds own 90.89% of the company’s stock.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Rein Therapeutics to a “sell” rating in a report on Saturday, May 16th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $8.00.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.